STUDY SEARCH RESULTS

2 studies found for your search request:  4280A-007

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects Wit...
Condition: Colorectal cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05064059
Status: Completed
Has Results

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects Wit...
Condition: Colorectal cancer
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05600309
Status: Completed




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site